Poster at ADLM: Calprotectin in Hidradenitis Suppurativa (HS)

Poster session: Calprotectin as a biomarker in Hidradenitis suppurativa (HS)

Don't miss the opportunity to delve deeper into this ground-breaking development and engage with us at the poster session: B-068. Plasma calprotectin as an index of draining tunnel formation in Hidradenitis suppurativa.

Hidradenitis suppurativa (HS) - Chronic inflammatory skin disorder

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder affecting areas rich in apocrine glands. The main disease manifestations are inflammatory nodules (IN) and dTs. IN appear in the affected areas, which gradually become swollen and rupture with the release of pus. This process occurs repeatedly leading to formation of dT and scars. dT are the main driver of flare-ups and of the deterioration of the quality of life.

The biomarker calprotectin, also known as S100A8/A9 protein, has been shown to be involved in various inflammatory conditions, including HS. The objective of this study is to evaluate circulating calprotectin as an index of draining tunnels (dT) in the affected skin. ​There is currently lack of any broadly accepted biomarker which may inform on the activity of hidradenitis suppurativa. The existence of a biomarker which may predict dT formation before dTs appear in skin may become a tool for early biological treatment. 

Plasma calprotectin as an index of draining tunnel formation in HS

In the poster B-068. Plasma calprotectin as an index of draining tunnel formation in Hidradenitis suppurativa calprotectin is presented as a biomarker which could be used for assessment of the disease severity in patients with hidradenitis suppurativa. 

Correlation of circulating calprotectin with number of draining tunnels and iHS4 score indicates the value of the biomarker in assessment of formation of draining tunnels and identification of patients with severe form of the disease. The use of calprotectin as a surrogate biomarker for early start of the therapy and response to treatment will be explored.

Gentian Calprotectin GCAL® Immunoassay* 

GCAL^® is a Particle-Enhanced Turbidimetric Immunoassay (PETIA) rapidly performed in only 10 minutes. As open channel assay it is available on a wide range of clinical chemistry platforms.

The assay is not cleared for use in the USA. The assay is IVDR certified.

Get in touch with Gentian

Want to know more? Meet us at booth #3210 at ADLM 2024. Book a meeting by sending an email to marketing@gentian.com or fill out the form below:

* Gentian's plasma and serum calprotectin immunoassay is not cleared for use in the USA.

This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances.